Cytosorbents Corporation
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-8.2M | $-20.7M | $-29.2M | $-32.8M | $-24.6M | $-7.8M | $-19.3M | $-17.2M |
| Depreciation & Amortization | $1.2M | $1.3M | $1.5M | $882.6K | $731.6K | $660.8K | $581.5K | $390.6K |
| Depreciation | $1.2M | $1.3M | $1.2M | $688.6K | $571.2K | $553.9K | $495.7K | $329.5K |
| Amortization | $262.0K | $235.0K | — | — | — | — | — | — |
| Stock-Based Compensation | $2.8M | $3.8M | $4.2M | $3.4M | $4.0M | $3.5M | $1.7M | $4.4M |
| Net Cash from Operating Activities | $-12.4M | $-14.4M | $-21.7M | $-28.2M | $-14.0M | $-5.6M | $-16.8M | $-10.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $164.0K | $284.0K | $538.1K | $6.1M | $3.6M | $708.4K | $698.2K | $672.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-415.0K | $-669.0K | $-936.2K | $-6.5M | $-4.3M | $-1.7M | $-1.5M | $-1.5M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $9.3M | $9.3M | $14.5M | $5.0M | $715.2K | $66.3M | $8.2M | $17.5M |
| Net Change in Cash | $-2.0M | $-5.9M | $-8.2M | $-30.0M | $-17.6M | $59.2M | $-10.1M | $5.0M |
| Free Cash Flow | $-12.5M | $-14.7M | $-22.2M | $-34.3M | $-17.6M | $-6.3M | $-17.5M | $-11.5M |